Alkermes’ diverse product portfolio reflects our powerful expertise in the development of innovative patient-inspired solutions. Our products are based on proprietary science and technology that provide unique treatment options for patients with debilitating diseases.
In particular, Alkermes is focused on drug development for central nervous system (CNS) diseases, a therapeutic area where we have a proven track record. Our aim is to develop new medicines that make significant advances for chronic CNS conditions that affect millions of patients, such as schizophrenia, major depressive disorder and multiple sclerosis. Click here to learn about our strong pipeline of innovative product candidates.